BTTX — Better Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $0.62m
- $8.33m
Annual cashflow statement for Better Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -0.002 | -40.3 | -39.8 |
| Depreciation | |||
| Deferred Taxes | |||
| Non-Cash Items | — | 10.4 | 1.83 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 0.001 | -2.34 | 6.27 |
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -0 | -30.8 | -28.9 |
| Capital Expenditures | — | -1.07 | -1.18 |
| Purchase of Fixed Assets | |||
| Software Development Costs | |||
| Cash from Investing Activities | — | -1.07 | -1.18 |
| Financing Cash Flow Items | -0.062 | 62.3 | 0 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 0.025 | 72.3 | 5.28 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.025 | 40.4 | -24.8 |